Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/24084
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZeng, Yaping
dc.contributor.authorCavalcante, Rafael
dc.contributor.authorTenekecioglu, Erhan
dc.contributor.authorSuwannasom, Pannipa
dc.contributor.authorSotomi, Yohei
dc.contributor.authorCollet, Carlos
dc.contributor.authorAbdelghani, Mahammad
dc.contributor.authorJonker, Hans
dc.contributor.authorDigne, Franck
dc.contributor.authorHorstkotte, Dieter
dc.contributor.authorZehender, Manfred
dc.contributor.authorIndolfi, Ciro
dc.contributor.authorSaia, Francesco
dc.contributor.authorFiorilli, Rosario
dc.contributor.authorChevalier, Bernard
dc.contributor.authorBolognese, Leonardo
dc.contributor.authorGoicolea, Javier
dc.contributor.authorNie, Shaoping
dc.contributor.authorOnuma, Yoshinobu
dc.contributor.authorSerruys, Patrick W
dc.date.accessioned2019-06-28T14:05:22Z-
dc.date.available2019-06-28T14:05:22Z-
dc.date.issued2017-04
dc.identifier.citationInt J Cardiovasc Imaging.2017 Apr;(33)4:441-449
dc.identifier.urihttps://hdl.handle.net/20.500.12530/24084-
dc.description.abstractThe purpose of the study to assess the comparability of immediate changes in plaque/media volume (PV) on three modalities of intravascular ultrasound (IVUS) after implantation of either bioresorbable vascular scaffold (BVS) or everolimus-eluting metallic stent (EES) in Absorb II Study. The two devices have different device volume and ultrasound backscattering that may interfere with the "plaque/media" assessed by three modalities on IVUS: grayscale, backscattering of radiofrequency and brightness function. In a multicenter randomized controlled trial, 501 patients with stable or unstable angina underwent documentary IVUS pre- and post- implantation. The change in plaque/media volume (PV) was categorized into three groups according to the relative PV change in device segment: PV "increased" >+5% (PVI), PV unchanged ±5% (PVU), and PV decreased <-5% (PVD). The change in PV was re-evaluated three times: after subtraction of theoretical device volume, after analysis of echogenicity based on brightness function. In 449 patients, 483 lesions were analyzed pre- and post-implantation. "PVI" was more frequently observed in BVS (53.8%) than EES group (39.4%), p = 0.006. After subtraction of the theoretical device volume, the frequency of "PVI" decreased in both BVS (36.2%) and EES (32.1%) groups and became comparable (p = 0.581). In addition, the percentage of "PVI" was further reduced in both device groups after correction for either radiofrequency backscattering (BVS 34.4% vs. EES 22.6%) or echogenicity (BVS 25.2% vs. EES 9.7%). PV change in device segment was differently affected by BVS and EES devices implantation due to their differences in device volume and ultrasound backscattering. It implies that the lumen volume was also artifactually affected by the type of device implanted. Comparative IVUS assessment of lumen and plaque/media volume changes following implantation of BVS and EES requires specific methodological adjustment.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectAbsorb II
dc.subjectBioresorbable vascular scaffold
dc.subjectIVUS
dc.subjectPlaque/media volume
dc.subject.meshAged
dc.subject.meshCardiovascular Agents
dc.subject.meshCarotid Artery Diseases
dc.subject.meshCoronary Vessels
dc.subject.meshDatabases, Factual
dc.subject.meshEverolimus
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImage Interpretation, Computer-Assisted
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPercutaneous Coronary Intervention
dc.subject.meshPredictive Value of Tests
dc.subject.meshProspective Studies
dc.subject.meshProsthesis Design
dc.subject.meshSingle-Blind Method
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshAbsorbable Implants
dc.subject.meshDrug-Eluting Stents
dc.subject.meshMetals
dc.subject.meshPlaque, Atherosclerotic
dc.subject.meshUltrasonography, Interventional
dc.titleComparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
dc.typeArtículo
dc.identifier.pubmedID28012050
dc.format.volume33
dc.format.page441-449
dc.identifier.e-issn1875-8312
dc.identifier.journalThe international journal of cardiovascular imaging
dc.identifier.doi10.1007/s10554-016-1033-7
dc.format.number4
dc.identifier.pmcPMC5357282
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeRandomized Controlled Trial
Appears in Collections:Hospitales > H. U. Puerta de Hierro Majadahonda > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Puerta de Hierro-Segovia de Arana > Artículos

Files in This Item:
File Description SizeFormat 
PMC5357282.pdf1.06 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.